Carlos Solano Vercet-rekin lankidetzan egindako argitalpenak (16)

2021

  1. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

2002

  1. Hematopoietic stem cell transplantation in patients or from donors with hepatitis B or C virus infection: Review and recommendations

    Medicina Clinica

2001

  1. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation

    Bone Marrow Transplantation, Vol. 27, Núm. 3, pp. 287-293

  2. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation

    Journal of Clinical Microbiology, Vol. 39, Núm. 11, pp. 3938-3941

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome

    Bone Marrow Transplantation, Vol. 25, Núm. 11, pp. 1203-1208

  3. Delayed graft-versus-leukemia effect after allogeneic peripheral stem cell transplantation in a patient with chronic lymphocytic leukemia

    Haematologica, Vol. 85, Núm. 3, pp. 330-332

1999

  1. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC)

    Bone Marrow Transplantation, Vol. 23, Núm. 11, pp. 1101-1107

  2. Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis

    Cancer Genetics and Cytogenetics, Vol. 110, Núm. 2, pp. 111-114

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140

  2. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation

    Bone Marrow Transplantation, Vol. 22, Núm. 1, pp. 39-45

1997

  1. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica

    Sangre, Vol. 42, Núm. SUPPL. 1, pp. 34-41

  2. Tratamiento de mantenimiento con interferón alfa en mieloma múltiple tras autotrasplante de progenitores hematopoyéticos de sangre periférica. Registro Español de Trasplante en Mieloma.

    Sangre, Vol. 42 Suppl 1, pp. 38-41

1993

  1. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: A report from the Spanish GEL/TAMO Cooperative Group

    Annals of Hematology, Vol. 67, Núm. 3, pp. 111-114